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Two TRAbs: TSBAb and TSAb. TSBAb causes hypothyroidism. TSAb causes Graves’ hyperthyroidism. TSBAb and TSAb block
TSH-binding to cells as TRAb, measured as TSH-binding inhibitory immunoglobulin (TBII). We reevaluate TSBAb and TSAb.
We studied TSBAb, TSAb, and TBII over 10 years in 34 TSBAb-positives with hypothyroidism and in 98 TSAb-positives with
hyperthyroidism. Half of the 34 TSBAb-positives with hypothyroidism continued to have persistently positive TSBAb, continued
to have hypothyroidism, and did not recover from hypothyroidism. Ten of the 98 TSAb-positives with hyperthyroidism continued
to have positive TSAb and continued to have hyperthyroidism. TSBAb had disappeared in 15 of the 34 TSBAb-positives with
hypothyroidism. With the disappearance of TSBAb, recovery from hypothyroidism was noted in 13 (87%) of the 15 patients.
TSAb had disappeared in 73 of the 98 TSAb-positives with hyperthyroidism. With the disappearance of TSAb, remissions of
hyperthyroidism were noted in 60 (82%) of the 73. Two of the 34 TSBAb-positives with hypothyroidism developed TSAb-
positive Graves’ hyperthyroidism. Two of the 98 TSAb-positive Graves’ patients with hyperthyroidism developed TSBAb-positive
hypothyroidism. TSBAb and TSAb are TRAbs. TSBAb-hypothyroidism and TSAb-hyperthyroidism may be two aspects of one
disease (TRAb disease). Two forms of autoimmune thyroiditis: atrophic and goitrous. We followed 34 TSBAb-positive patients
with hypothyroidism (24 atrophic and 10 goitrous) over 10 years. All of the 10 TSBAb-positive goitrous patients recovered from
hypothyroidism and 19 (79%) of the 24 TSBAb-positive atrophic patients continued to have hypothyroidism.
1.Introduction
There are two types of TSH receptor antibodies (TRAbs):
thyroid stimulating antibody (TSAb) [1, 2] and TSH-stimu-
lation blocking antibody (TSBAb) [3]. TSAb stimulates the
thyroid and causes Graves’ hyperthyroidism. TSBAb blocks
TSH-stimulation of the thyroid and causes hypothyroidism.
Both TSAb and TSBAb block TSH-binding to thyroid cells as
TSH-receptorantibody(TRAb),whichhasbeenmeasuredas
TSH-bindinginhibitoryimmunoglobulin(TBII)[1–3].TBII
indicates the inhibition of TSH-binding to TSH receptor
but does not indicate the function of TRAb. TRAb can be
stimulatory or inhibitory. To know whether TRAb is stimu-
latory or inhibitory, TSAb and TSBAb have been measured
[1–3]. TRAb has been measured by diﬀerent assay methods
and given various names. Among them, TBII [1, 4, 5]a n d
TSAb [1, 2, 6–9] have been measured as TRAb to diagnose
Graves’ disease and to follow the patients. TBII is measured
as a receptor assay. TSAb is measured as a stimulator assay,
using porcine thyroid cells. TSAb indicates the stimulation2 Journal of Thyroid Research
activity of TRAb. TSBAb [3, 10–13]a n dT B I I[ 3, 4, 10–13]
have been measured as TRAb to diagnose TSBAb-positive
hypothyroidism and to follow the patients. TSBAb has been
measuredasaTSH-stimulationblockingassay,usingporcine
thyroidcells[3,10–13].TSBAbindicatestheinhibitoryactiv-
ity of TRAb. TSAb and TSBAb are TSH-receptor antibodies
(TRAb). The former TRAb (TSAb) is a stimulating antibody
[1, 2, 6–9], and the latter TRAb (TSBAb) is a blocking
antibody [3, 10–13]. TSBAb blocks TSH-stimulation of the
thyroid and causes hypothyroidism. TSBAb blocks TSH-
binding to thyroid cells and is TRAb. TSBAb blocks TSH-
stimulation of the thyroid and is measured as inhibition of
TSH-stimulated cAMP synthesis of thyroid cells. TSBAb and
TSAb are TRAb. TBII reﬂects TSBAb- and TSAb-activities.
TSAbstimulatesthethyroidandcausesGraves’hyperthy-
roidism. Treatment with antithyroid drugs (ATDs) decreases
serum TSAb [14]. With the disappearance of TSAb, remis-
sions of Graves’ hyperthyroidism have been seen [14].
TSBAb blocks TSH-stimulation of the thyroid and causes
hypothyroidism [3]. With the disappearance of TSBAb,
recovery from hypothyroidism occurs [3].
It has been generally believed that Graves’ patients have
TSAb but do not have TSBAb, and that blocking antibody-
(TSBAb-)positivepatientswithhypothyroidismhaveTSBAb
but do not have TSAb. However, TSBAb-positive patients
with hypothyroidism and TSAb-positive Graves’ patients
with hyperthyroidism could have both TSBAb and TSAb
[13]. Some patients may have TSBAb and TSAb simulta-
neously or sequentially [13]. The balance of TSBAb and
TSAb determines whether a patient has hypothyroidism or
hyperthyroidism [13]. We have encountered TSBAb-positive
patients with hypothyroidism, who developed TSAb-positive
Graves’ hyperthyroidism, and also TSAb-positive Graves’
patients with hyperthyroidism, who developed TSBAb-
positive hypothyroidism. Thyroid function can oscillate
between hypothyroidism and hyperthyroidism as TSBAb or
TSAb becomes dominant.
There are two forms of autoimmune thyroiditis: atrophic
autoimmune thyroiditis and goitrous autoimmune thyroidi-
tis[3].Ithasbecomeevidentthathypothyroidismmayoccur
as a result of the production of TSBAb. TSBAb has been
said to cause hypothyroidism in the patients with atrophic
autoimmune thyroiditis [3]. However, TSBAb has been
found in patients with atrophic autoimmune thyroiditis, and
also in patients with goitrous autoimmune thyroiditis [11].
TSBAb was detected in 25% of the patients with atrophic
autoimmune thyroiditis and in 9% of those with goitrous
autoimmune thyroiditis [3]. TSBAb causes hypothyroidism.
With the disappearance of TSBAb, recovery from hypothy-
roidism has been reported [3]. Here, we followed 24 TSBAb-
positive hypothyroid patients with atrophic autoimmune
thyroiditis and 10 TSBAb-positive hypothyroid patients
with goitrous autoimmune thyroiditis over 10 years. All of
the 10 TSBAb-positive patients with goitrous autoimmune
thyroiditis recovered from hypothyroidism and 19 (79%) of
the 24 TSBAb-positive patients with atrophic autoimmune
thyroiditis continued to have hypothyroidism.
We reevaluated TSBAb and TSAb in TRAb-positive
patients. We studied serial changes of TSBAb and TSAb
over 10 years in 34 TSBAb-positive patients with hypothy-
roidism and in 98 TSAb-positive Graves’ patients with
hyperthyroidism. With persistently positive TSBAb, recovery
from hypothyroidism was not observed. With persistently
positive TSAb, remissions of Graves’ hyperthyroidism were
not obtained. With the disappearance of TSBAb, recovery
from hypothyroidism was seen. With the disappearance of
TSAb, remissions of Graves’ hyperthyroidism were also seen.
Two of the 34 TSBAb-positive patients with hypothyroidism
developed TSAb-positive Graves’ hyperthyroidism. Two of
the 98 TSAb-positive Graves’ patients with hyperthyroidism
developed TSBAb-positive hypothyroidism. TSBAb-positive
hypothyroidism and TSAb-positive hyperthyroidism may be
two aspects of one disease (TRAb disease).
2.SubjectsandMethod
2.1. Subjects. We studied 34 TSBAb-positive patients with
hypothyroidism and 98 TSAb-positive Graves’ patients with
hyperthyroidism (Table 1). The 34 TSBAb-positive patients
with hypothyroidism were treated with thyroxine (T4) and
the 98 TSAb-positive Graves’ patients with hyperthyroidism
were treated with antithyroid drugs (ATDs). Serial changes
of TSBAb and TSAb over 10 years were studied in 34 TSBAb-
positive patients with hypothyroidism (I) and in 98 TSAb-
positive Graves’ patients with hyperthyroidism (II). TSBAb-
positive patients with hypothyroidism were diagnosed on
the basis of the history, signs of hypothyroidism, and the
laboratory ﬁndings, including positive TSBAb (>+40%) and
decreased serum-free thyroxine (fT4) and free triiodothyro-
nine (fT3) with high TSH [3, 13]. The diagnosis of goitrous
autoimmune thyroiditis was based on the ﬁnding of palpable
goiter and that of atrophic autoimmune thyroiditis on the
absence of goiter [3]. The 34 TSBAb-positive patients with
hypothyroidism were treated with thyroxine (T4). Thyroxine
was discontinued at 3 months after the disappearance of
TSBAb. After the discontinuation of T4, the patients had
been seen every 1–3 months. When the patients continued
to be in euthyroid states and to have negative TSBAb
and negative TBII for more than 1 year after the T4-
discontinuation, they were considered to have recovery
from hypothyroidism; otherwise, they had recurrence [3].
When serum TSH became higher than 10mIU/L, T4-
administration was restarted [3]. TSAb-positive Graves’
patients with hyperthyroidism were diagnosed on the basis
of the history, signs of hyperthyroidism with diﬀuse goiter,
and the laboratory ﬁndings, including positive TRAb (TSAb
and/or TBII) and elevated fT4 and fT3 with low TSH [1,
2]. The 98 Graves’ patients were treated with antithyroid
drugs (ATDs). They had been treated with ATD over
several years. ATD was discontinued at 6 months after the
TSAb-disappearance. After the discontinuation of ATD, the
patients had been seen every 1–3 months. When the patients
continued to be in euthyroid states and to have negative
TSAb and negative TBII for more than 1 year after the
ATD-discontinuation, they were considered to be in remis-
sion; otherwise, they had recurrence [14]. When they had
recurrence, ATD-treatment was restarted. We had followed
these 34 TSBAb-positive patients with hypothyroidism andJournal of Thyroid Research 3
Table 1: Changes of TSBAb (TSH-stimulation blocking antibody) and TSAb (thyroid stimulating antibody) over 10 years in 34 TSBAb-
positive patients with hypothyroidism and in 98 TSAb-positive Graves’ patients with hyperthyroidism.
(I) 34 TSBAb-positive patients with hypothyroidism 34
Ia: Positive TSBAb persisted Continued to have hypothyroidism 17 17
Ib: TSBAb disappeared Ib1: Recovered from hypothyroidism 13 15
Ib2: Continued to have hypothyroidism 2
Ic: TSBAb→ TSAb TSBAb-positive hypo → Graves’ hyper 2 2
(II) 98 TSAb-positive Graves’ patients with hyperthyroidism 98
IIa: Positive TSAb persisted Continued to have Graves’ hyperthyroidism 10 10
IIb: Complex changes of TSAb IIb1: Remission 1 13
IIb2: Recurrence 12
IIc: TSAb disappeared IIc1: Remission 60 73
IIc2: Recurrence 13
IId: TSAb → TSBAb Graves’ hyper → TSBAb-positive hypo 2 2
Numbers of the patients are shown.
Serial changes of TSBAb and TSAb over 10 years were studied in 34 TSBAb-positive patients with hypothyroidism (I) and in 98 TSAb-positive Graves’ patients
with hyperthyroidism (II). The 34 TSBAb-positive patients with hypothyroidism were treated with thyroxine (T4) and the 98 TSAb-positive Graves’ patients
withhyperthyroidismweretreated withantithyroiddrugs (ATDs).Half(17) (Ia)ofthe34TSBAb-positivepatientswithhypothyroidism(I)continuedt oha v e
positiveTSBAbandcontinuedtohavehypothyroidism.Ten(IIa)ofthe98TSAb-positiveGraves’patientswithhyperthyroidism(II)continuedtohavepositive
TSAb and continued to have Graves’ hyperthyroidism. With the disappearance of TSBAb, recovery from hypothyroidism was noted in 13 (Ib1) (87%) of the
15 patients, in whom TSBAb had disappeared (Ib). With the disappearance of TSAb, remissions of Graves’ hyperthyroidism were noted in 60 (IIc1) (82%) of
the 73, in whom TSAb had disappeared (IIc). Two of the 34 TSBAb-positive patients with hypothyroidism developed TSAb-positive Graves’ hyperthyroidism
(Ic), and two of the 98 TSAb-positive Graves’ patients with hyperthyroidism developed TSBAb-positive hypothyroidism (IId).
98TSAb-positiveGraves’patientswithhyperthyroidismover
10 years.
2.2. Porcine Thyroid Cell Cyclic AMP Production: TSBAb and
TSAb. TSBAb and TSAb were measured as before [13, 14].
Cyclic AMP (cAMP) production was determined according
to the instruction in commercial assay kit (Yamasa, Chosi,
Chiba, Japan). Crude IgG, obtained as PEG (6000) 12.5%
precipitated fraction- (ﬁnal concentration) from 0.2mL
aliquot of test serum, was dissolved in modiﬁed Hanks’
solution without NaCl. Porcine thyroid cells were incubated
with test IgG in 0.25mL Hanks’ solution without NaCl, pH
7.5, containing 1.5% bovine serum albumin, 20mM Hepes,
and 0.5mM 3-isobutyl-l-methylxanthine. Cyclic AMP pro-
duction during 5h incubation at 37◦C was measured by
radioimmunoassay (RIA), using a commercial kit (Yamasa).
To measure TSBAb-activities, crude IgG was incubated
with porcine thyroid cells in the presence of 25μUb T S H
(100mU/L, ﬁnal concentration), as before [3, 10–13, 15].
CyclicAMPproductionduring5hincubationwasmeasured.
TSBAb-activity was expressed as percentage inhibition of
bTSH-stimulated cAMP production by test IgG. TSBAb-
activity was calculated as follows:TSBAb (%) = [1 − (c −
b)/(a − b)] × 100 [3, 10–13, 15], where a: cAMP generated
in the presence of normal IgG and bTSH, b:c A M Pg e n e r a t e d
in the presence of normal IgG, and c: cAMP generated in the
presenceoftestIgGandbTSH.TestIgGandnormalIgGwere
the 12.5% PEG-precipitated fraction from test serum and
normal human serum, respectively. TSBAb, described in this
report, corresponds to TSBAb-A in the previous report [13].
TSBAb activities were studied in 95 normal subjects (normal
values were less than +40%) [13]. TSBAb activities were
more than +40% in all of the TSBAb-positive patients with
hypothyroidism. TSAb activity was expressed as percentage
cAMP production compared with the mean values for 125
normal subjects (normal values were less than 180%) [1, 2,
14]: TSAb (%) = [d/b] × 100, where b:c A M Pg e n e r a t e di n
the presence of normal IgG, and d: cAMP generated in the
presence of test IgG.
2.3. TSH-Binding Inhibitory Immunoglobulin (TBII). TBII
was measured by radioreceptor assay with a commercial kit
(R. S. R. Limited, Cardiﬀ, UK). Assay results were expressed
as the percentage inhibition of I125-TSH-binding to thyroid
plasma membrane as before [1, 2, 5, 14]. Normal values were
obtained from 128 normal control subjects and were less
than l0% [1, 2, 14].
2.4. Statistical Analysis and Others. All samples were tested
in duplicate or triplicate. Statistical analysis was performed
using Student’s t-test or χ2-test. P values less than 0.05 were
considered to be statistically signiﬁcant. Serum-free T3, -free
T4, and TSH were determined by electrochemiluminescence
immunoassays (ECLIAs) (Roche Diagnostics, Tokyo, Japan).
Normal reference ranges are as follows: fT3 3.5–6.6nmol/L,
fT4 11.6–21.9pmol/L, and TSH 0.4–4.20mIU/L. The study
plan was reviewed and approved by our institutional review
committee.Writteninformedconsentwasobtainedfromthe
patient prior to publication of this paper.
3. Resuls
Serial changes of TSBAb and TSAb over 10 years were
studied in 34 TSBAb-positive patients with hypothyroidism
and in 98 Graves’ patients with hyperthyroidism (Table 1).
The 34 TSBAb-positive patients with hypothyroidism (I)
were treated with thyroxine (T4) and the 98 TSAb-positive4 Journal of Thyroid Research
Table 2: Characteristics of the 34 TSBAb-positive patients with hypothyroidism and the 98 TSAb-positive Graves’ patients with hyperthy-
roidism.
Number of patients Gender Age (years) Before treatment
Men/Women TSBAb (%) TSAb (%) TBII (%)
(I) 34 TSBAb-positive patients with hypothyroidism
Ia 17 5/12 42 ± 17 94 ± 6 146 ± 10 95 ±5
Ib 15 4/11 45 ± 16 90 ± 9 136 ± 8 92 ±7
Ic 2 1/1 38, 45 98, 97 100, 98 96, 95
Ia+Ib+Ic 34 10/24 43 ± 18 92 ± 7 140 ± 9 94 ±7
(II) 98 TSAb-positive Graves’ patients with hyperthyroidism
IIa 10 3/7 40 ± 16 9 ± 8 839 ±421 76 ±15
IIb 13 3/10 42 ± 17 10 ± 11 846 ±195 68 ±16
IIc 73 18/55 44 ± 16 10 ± 10 746 ±390 56 ±18
IId 2 0/2 40, 48 2, 5 1625, 852 76, 58
IIa+IIb+IIc+IId 98 24/74 43 ± 17 10 ± 9 775 ±396 57 ±17
Values are means ± SD. I, Ia, Ib, Ic, II, IIa, IIb, IIc, and IId correspond to those in Table 1.N od i ﬀerences of gender and ages were noted among I, Ia, Ib, Ic, II,
IIa, IIb, IIc, and IId. No diﬀerences of TSAb-, TSBAb-, and TBII-activities were noted among Ia, Ib, and Ic and among IIa, IIb, IIc, and IId.
All of the 34 TSBAb-positive patients with hypothyroidism had strongly positive TSBAb (85–103%, mean ± SD = 92 ± 7%) (Ia+Ib+Ic). Some of them had
weakly positive TSAb. Their TSAb activity ranged from 92% to 240%. The TSAb activities were 180–240% in 7 (21%) of the 34 TSBAb-positive patients with
hypothyroidism and were less than 180% in the other 27 patients (79%). Seven (21%) of the 34 TSBAb-positive patients with hypothyroidism had positive
TSAb. TSBAb-positive patients with hypothyroidism had narrow distribution of TSBAb (82–104%, 92 ± 7%) and TSAb (92–240%, 140 ± 9%). All of the 98
Graves’ patients with hyperthyroidism had positive TSAb (250–1795%, 775 ± 396%) (IIa+IIb+IIc+IId). Some of them had TSBAb. The TSBAb activities were
+40–+52% in 11 (11%) and were less than +40% in the other 87 patients (89%). Graves’ patients with hyperthyroidism had wide distributions of TSAb (250–
1795%, 775 ± 396%) and TSBAb (−28–+52%, 10 ± 9%).
Graves’ patients with hyperthyroidism (II) were treated with
antithyroid drugs (ATDs). Among the 34 TSBAb-positive
patients with hypothyroidism (I), 17 patients (Ia) continued
to have persistently positive TSBAb and continued to have
hypothyroidism. Half (17) (Ia) of the 34 TSBAb-positive
patients continued to have persistently positive TSBAb,
continued to have hypothyroidism, and did not recover
from hypothyroidism. TSBAb disappeared in 15 (Ib) of
the 34 TSBAb-positive patients with hypothyroidism. With
the disappearance of TSBAb, recovery from hypothyroidism
was seen in 13 (Ib1) (87%) of the 15 patients, in whom
TSBAb had disappeared (Ib). Among the 98 TSAb-positive
Graves’ patients with hyperthyroidism (II), 10 patients (IIa)
continued to have persistently positive TSAb and continued
tohavehyperthyroidism.Tenofthe98TSAb-positiveGraves’
patientswithhyperthyroidismcontinuedtohavepersistently
positive TSAb. They continued to have hyperthyroidism and
did not get remissions of Graves’ hyperthyroidism. They
continued to take ATD. Complex changes of TSAb were
noted in 13 TSAb-positive patients (IIb). One (IIb1) of the
13 patients with complex changes of TSAb got remissions,
but the other 12 patients (IIb2) did not. TSAb disappeared
in 73 (IIc) (74%) of the 98 TSAb-positive Graves’ patients
with hyperthyroidism. With the disappearance of TSAb, 60
(IIc1) (82%) of the 73 patients, in whom TSAb had disap-
peared (IIc), got remissions of Graves’ hyperthyroidism. Two
TSBAb-positive patients with hypothyroidism developed
TSAb-positive Graves’ hyperthyroidism (Ic). Two TSAb-
positive Graves’ patients with hyperthyroidism developed
TSBAb-positive hypothyroidism (IId).
Table 2 shows characteristics of the 34 TSBAb-positive
patients with hypothyroidism (I) and the 98 TSAb-positive
Graves’ patients with hyperthyroidism (II). I, Ia, Ib, Ic, II,
IIa, IIb, IIc, and IId correspond to those in Table 1.N o
diﬀerences of gender and ages were noted among I, Ia,
Ib, Ic, II, IIa, IIb, IIc, and IId. No diﬀerences of TSAb-,
TSBAb-, and TBII-activities were noted among Ia, Ib, and
Ic and among IIa, IIb, IIc, and IId. All of the 34 TSBAb-
positive patients with hypothyroidism had strongly positive
TSBAb (85–103%, mean ± SD = 92 ± 7%) (Table 2,
Ia+Ib+Ic). Some of them had weakly positive TSAb. Their
TSAbactivityrangedfrom92%to240%.TheTSAbactivities
were 180–240% in 7 (21%) of the 34 TSBAb-positive
patients with hypothyroidism and were less than 180% in
the other 27 patients (79%). Seven (21%) of the 34 TSBAb-
positive patients with hypothyroidism had positive TSAb.
TSBAb-positive patients with hypothyroidism had narrow
distribution of TSBAb (82–104%, 92 ± 7%) and TSAb
(92–240%, 140 ± 9%). All of the 98 Graves’ patients with
hyperthyroidism had positive TSAb (250–1795%, 775 ±
396%)(Table 2,IIa+IIb+IIc+IId).SomeofthemhadTSBAb.
The TSBAb activities were +40–+ 52% in 11 (11%) and
were less than +40% in the other 87 patients (89%). Graves’
patients with hyperthyroidism had wide distributions of
TSAb (250–1795%, 775 ± 396%) and TSBAb (−28–+52%,
10 ± 9%).
3.1. 34 TSBAb-Positive Patients with Hypothyroidism (I)
(Tables 1 and 2,I ) .All of the 34 TSBAb-positive patients
with hypothyroidism had strongly positive TSBAb. Some
of them had weakly positive TSAb. TSBAb-positive patients
with hypothyroidism had narrow distributions of TSBAb
(82–104%, 92 ± 7%) and TSAb (92–240%, 140 ± 9%)
(Table 2, Ia+b+c). Figure 1 shows the changes of TSBAbJournal of Thyroid Research 5
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Figure1:ThechangesofTSBAbin34TSBAb-positivepatientswithhypothyroidism(Table 1,I).Amongthe34TSBAb-positivepatientswith
hypothyroidism, 17 patients continued to have persistently positive TSBAb and continued to have hypothyroidism (Table 1, Ia) (a). Half of
the 34 TSBAb-positive patients continued to have persistently positive TSBAb, continued to have hypothyroidism, and did not recover from
hypothyroidism. They continued to take thyroxine (T4). TSBAb disappeared in 15 of the 34 TSBAb-positive patients with hypothyroidism
(Table 1, Ib) (b). Recovery from hypothyroidism was noted with the disappearance of TSBAb in 13 (87%) of the 15 patients, in whom
TSBAb had disappeared. (c1, c2) show the changes of TSBAb and TSAb, respectively, in the 2 patients with TSBAb-positive hypothyroidism,
who developed TSAb-positive Graves’ hyperthyroidism (Table 1, Ic). In these 2 patients, TSBAb was dominant initially (c1), and then TSAb
becamedominant(c2);2patientswithTSBAb-positivehypothyroidismdevelopedTSAb-positiveGraves’hyperthyroidism.Hypothyroidism
wastreatedwiththyroxine(T4).Graves’hyperthyroidismwastreatedwith1-methyl2-mercaptoimidazole(MMI).TSBAb:TSH-stimulation
blocking antibody; TSAb: thyroid stimulating antibody.
in the 34 TSBAb-positive patients with hypothyroidism
(Table 1, I). Among the 34 TSBAb-positive patients with
hypothyroidism (I), 17 (Ia) (Table 1,I a ,Figure 1(a)) con-
tinued to have persistently positive TSBAb and continued
to have hypothyroidism. Half (17) (Ia) of the 34 TSBAb-
positive patients (I) continued to have persistently positive
TSBAb, continued to have hypothyroidism, and did not
recover from hypothyroidism. They continued to take T4.
TSBAbdisappearedin15(Ib)(Table 1,Ib ,Figure 1(b))ofthe
34 TSBAb-positive patients (I) with hypothyroidism. With
the disappearance of TSBAb, recovery from hypothyroidism
was noted in 13 (Ib1) (87%) of the 15 patients, in whom
TSBAb had disappeared (Ib).
Figures 1(c1) and 1(c2) show the changes of
TSBAb and TSAb, respectively, in the 2 patients with
TSBAb-positive hypothyroidism, who developed TSAb-
positive Graves’ hyperthyroidism (Table 1, Ic). In these
2 patients, TSBAb was dominant initially (Figure 1(c1)),
and then TSAb became dominant (Figure 1(c2)). These
2 TSBAb-positive patients had hypothyroidism and then
developed TSAb-positive Graves’ hyperthyroidism. They
were treated with T4 and then treated with 1-methyl
2-mercapto imidazole (MMI). Figure 2 demonstrates the
clinical course of one of these 2 patients with TSBAb-
positive hypothyroidism, who developed TSAb-positive
Graves’ hyperthyroidism (Table 1, Ic). A 45-year-old woman
with TSBAb-positive hypothyroidism developed TSAb-
positive Graves’ hyperthyroidism. TSBAb was dominant
initially (Figure 2(a)), and then TSAb became dominant
(Figure 2(b)). She had TSBAb-positive hypothyroidism with6 Journal of Thyroid Research
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Figure 2: The clinical course of one of the 2 patients, who initially had TSBAb-positive hypothyroidism and then developed TSAb-
positive Graves’ hyperthyroidism (Table 1, Ic). A 45-year-old woman with TSBAb-positive hypothyroidism developed TSAb-positive Graves’
hyperthyroidism. She had TSBAb-positive hypothyroidism ((a),  ) with high serum TSH ((b), ◦) and then developed TSAb-positive
Graves’ hyperthyroidism ((b), ) with undetectable serum TSH ((b), ◦). TSBAb was dominant initially ((a),  ), and then TSAb became
dominant ((b), ). TBII (TSH-binding inhibitory immunoglobulin) ((a), ◦) reﬂects TSBAb- and TSAb-activity. A patient with TSBAb-
positive hypothyroidism developed TSAb-positive Graves’ hyperthyroidism. She was treated with T4 and then with MMI.
high serum TSH and then developed TSAb-positive Graves’
hyperthyroidism with undetectable serum TSH. She was
treated with T4 and then treated with MMI. She had a goiter
initially and had goitrous autoimmune thyroiditis.
Among the 34 TSBAb-positive patients with hypothy-
roidism (Table 1, I), 24 had atrophic autoimmune thyroiditis
and 10 had goitrous autoimmune thyroiditis (Table 3(a)).
The 34 TSBAb-positive patients with hypothyroidism con-
sisted of 17 patients (a: positive TSBAb persisited), 15
patients (b: TSBAb disappeared), and 2 patients (c:
TSBAb → TSAb) (Table 3(a)). All of the 17 (a) patients
continued to have positive TSBAb and continued to have
hypothyroidism. All of the 17 (a) patients had atrophic
autoimmune thyroiditis and none of them had goitrous
autoimmune thyroiditis. TSBAb disappeared in the 15 (b)
patients: 13 (b1) (87%) of the 15 (b) patients recovered from
hypothyroidism and 2 (b2) (13%) of the 15 (b) patients con-
tinued to have hypothyroidism. Of the 13 (b1) patients, who
recoveredfromhypothyroidism,5hadatrophicautoimmune
thyroiditis and 8 had goitrous autoimmune thyroiditis. The
2 (b2) patients, who continued to have hypothyroidism, had
atrophic autoimmune thyroiditis. Of the 15 (b) patients, in
whom TSBAb had disappeared, 7 [5 (b1) + 2 (b2)] had
atrophic autoimmune thyroiditis and 8 [8 (b1)] had goitrous
autoimmune thyroiditis. Two (c) patients of the 34 TSBAb-
positive patients with hypothyroidism developed TSAb-
positive Graves’ hyperthyroidism had goitrous autoimmune
thyroiditis.
Table 3(b) demonstrates recovery from hypothyroidism
in the 34 TSBAb-positive patients with hypothyroidism
(24 patients with atrophic autoimmune thyroiditis and 10
patients with goitrous autoimmune thyroiditis). Among
the 34 TSBAb-positive patients with hypothyroidism, 19
[(17 (a) + 2 (b2)) in Table 3(a)] continued to have
hypothyroidism over 10 years and 15 [13 (b1) + 2 (c)]
recovered from hypothyroidism (13 (b1) recovered from
hypothyroidism and had remissions and 2 (c) recovered
from hypothyroidism and developed hyperthyroidism). All
of the 19 TSBAb-positive patients with hypothyroidism,
who continued to have hypothyroidism [17 (a) + 2 (b2)],
had atrophic autoimmune thyroiditis, and none of them
had goitrous autoimmune thyroiditis. Fifteen [13 (b1) + 2
(c)] of the 34 TSBAb-positive patients with hypothyroidism
recovered from hypothyroidism. Five [5 (b1)] of the 15
patients, who recovered from hypothyroidism, had atrophic
autoimmune thyroiditis and the other 10 [8 (b1) + 2 (c)]
had goitrous autoimmune thyroiditis. Nineteen (79%) of
the 24 TSBAb-positive hypothyroid patients with atrophic
autoimmune thyroiditis continued to have hypothyroidism
and the other 5 (21%) recovered from hypothyroidism. All
(100%) of the 10 TSBAb-positive hypothyroid patients with
goitrous autoimmune thyroiditis [8 (b1) + 2 (c)] recovered
from hypothyroidism. Signiﬁcant diﬀerences of recovery
from hypothyroidism were noted between the patients with
goitrous autoimmune thyroiditis and those with atrophic
autoimmune thyroiditis (χ2 = 17.9, P value < 0.05). All of
the 10 TSBAb-positive patients with goitrous autoimmune
thyroiditis recovered from hypothyroidism and 19 (79%)
of the 24 patients with atrophic autoimmune thyroiditis
continued to have hypothyroidism.
3.2. 98 TSAb-Positive Graves’ Patients with Hyperthyroidism
(II) (Tables 1 and 2, II). All of the 98 Graves’ patientsJournal of Thyroid Research 7
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Figure 3: The changes of TSAb in 98 Graves’ patients with hyperthyroidism (II) (Table 1, II). Among the 98 Graves’ patients with
hyperthyroidism, 10 patients continued to have persistently positive TSAb and continued to have hyperthyroidism (Table 1,I I a )( a ) .T e n
of the 98 TSAb-positive Graves’ patients with hyperthyroidism continued to have persistently positive TSAb. They continued to have
hyperthyroidism and did not get remissions of Graves’ hyperthyroidism. They continued to take MMI. Complex changes of TSAb were
noted in 13 TSAb-positive patients (Table 1, IIb) (b). One of the 13 patients with complex changes of TSAb got remissions, but the other 12
patients did not get remissions. TSAb disappeared in 73 (74%) of the 98 TSAb-positive Graves’ patients with hyperthyroidism (Table 1,I I c )
(c).WiththedisappearanceofTSAb,60(82%)ofthe73patients,inwhomTSAbhaddisappeared,gotremissionsofGraves’hyperthyroidism.
(d1, d2) show the changes of TSAb and TSBAb, respectively, in the 2 patients with TSAb-positive Graves’ hyperthyroidism, who developed
TSBAb-positive hypothyroidism (Table 1, IId). In these 2 patients, TSAb was dominant initially (d1), and then TSBAb became dominant
(d2). Two patients with TSAb-positive Graves’ hyperthyroidism developed TSBAb-positive hypothyroidism. Graves’ hyperthyroidism was
treated with MMI, and hypothyroidism was treated with T4.8 Journal of Thyroid Research
Table 3: Atrophic autoimmune thyroiditis or goitrous autoimmune thyroiditis in the 34 TSBAb (TSH-stimulation-blocking-antibody)-
positive patients with hypothyroidism (a) and recovery from hypothyroidism (b).
(a) Atrophic autoimmune thyroiditis (atrophic) or goitrous autoimmune thyroiditis (goitrous) in the 34 TSBAb-positive patients with hypothyroidism
34 TSBAb-positive patients with hypothyroidism (I in Table 1)† 34
Atrophic (24) Goitrous (10)
a: Positive TSBAb persisted
(Ia) 17 17 0
b: TSBAb disappeared (Ib) 15 b1: recovered (Ib1) 13 5 8
b2: hypothyroid (Ib2) 2 2 0
c: TSBAb → TSAb (Ic) 2 0 2
Numbers of the patients are shown. (I in Table 1)† correspond to those in Table 1
Among the 34 TSBAb-positive patients with hypothyroidism (Table 1, I), 24 had atrophic autoimmune thyroiditis and 10 had goitrous autoimmune
thyroiditis. The 34 TSBAb-positive patients with hypothyroidism consisted of 17 patients (a: positive TSBAb persisited), 15 patients (b: TSBAb
disappeared), and 2 patients (c: TSBAb → TSAb). All of the 17 (a) patients continued to have positive TSBAb and continued to have hypothyroidism.
Allofthe17(a)patientshadatrophicautoimmunethyroiditisandnoneofthemhadgoitrousautoimmunethyroiditis.TSBAbdisappearedinthe15(b)
patients:13(b1)(87%)ofthe15(b)patientsrecoveredfromhypothyroidismand2(b2)(13%)ofthe15(b)patientscontinuedtohavehypothyroidism.
Of the 13 (b1) patients, who recovered from hypothyroidism,5 had atrophic autoimmune thyroiditisand 8 had goitrous autoimmune thyroiditis. The 2
(b2) patients, who continued to have hypothyroidism, had atrophic autoimmune thyroiditis. Of the 15 (b) patients, in whom TSBAb had disappeared,
7 [5 (b1) + 2 (b2)] had atrophic autoimmune thyroiditis and 8 [8 (b1)] had goitrous autoimmune thyroiditis. Two (c) patients of the 34 TSBAb-positive
patients with hypothyroidism who developed TSAb-positive Graves’ hyperthyroidism who had goitrous autoimmune thyroiditis.
(b) Recovery from hypothyroidism in the patients with atrophic autoimmune thyroiditis (atrophic) and in those with goitrous autoimmune thyroiditis
(goitrous)
Atrophic (24) Goitrous (10)
Continued to have hypothyroidism 19 (79%)
[17 (a)+ 2 (b2)]∗ 0( 0 % ) 1 9
χ2 = 17.9 P value < 0.05
Recovered from hypothyroidism 5 (21%)
[5 (b1)]∗
10 (100%)
[8 (b1)+2 (c)]
∗ 15
24 (100%) 10 (100%) 34
Numbers (%) of the patients are shown. [ ]∗ corresponds to Table 3(a).
Among the 34 TSBAb-positive patients with hypothyroidism (Table 1, I), 24 had atrophic autoimmune thyroiditis and 10 had goitrous autoimmune
thyroiditis. Among the 34 TSBAb-positive patients with hypothyroidism, 19 [(17 (a) + 2 (b2)] (Table 3(a)) continued to have hypothyroidism over 10
years and 15 [13 (b1) + 2 (c)] recovered from hypothyroidism [13 (b1) recovered from hypothyroidism and had remissions and 2 (c) recovered from
hypothyroidism and developed hyperthyroidism]. All of the 19 TSBAb-positive patients with hypothyroidism, who continued to have hypothyroidism
[17 (a) + 2 (b2)], had atrophic autoimmune thyroiditis, and none of them had goitrous autoimmune thyroiditis. Fifteen [13 (b1) + 2 (c)] of the 34
TSBAb-positive patients with hypothyroidism recovered from hypothyroidism. Five [5 (b1)] of the 15 patients, who recovered from hypothyroidism,
had atrophic autoimmune thyroiditis and the other 10 [8 (b1) + 2 (c)] had goitrous autoimmune thyroiditis. Nineteen (79%) of the 24 TSBAb-
positive hypothyroid patients with atrophic autoimmune thyroiditis continued to have hypothyroidism and the other 5 (21%) of them recovered
from hypothyroidism. All of the 10 TSBAb-positive hypothyroid patients with goitrous autoimmune thyroiditis [8 (b1) + 2 (c)] recovered from
hypothyroidism. Signiﬁcant diﬀerences of recovery from hypothyroidism were noted between the patients with goitrous autoimmune thyroiditis and
those with atrophic autoimmune thyroiditis (χ2 = 17.9, P value < 0.05). All (100%) of the 10 TSBAb-positive patients with goitrous autoimmune
thyroiditis recovered from hypothyroidism and 19 (79%) of the 24 patients with atrophic autoimmune thyroiditis continued to have hypothyroidism.
with hyperthyroidism had positive TSAb. Some of them had
positive TSBAb. Graves’ patients with hyperthyroidism had
wide distributions of TSAb and TSBAb. Some of the Graves’
patients had both positive TSAb and TSBAb. Figure 3 shows
the changes of TSAb in 98 Graves’ patients with hyperthy-
roidism(II)(Table 1,II).Amongthe98Graves’patientswith
hyperthyroidism, 10 patients continued to have persistently
positive TSAb and continued to have hyperthyroidism (IIa)
(Figure 3(a)). Ten of the 98 TSAb-positive Graves’ patients
with hyperthyroidism continued to have positive TSAb and
continued to have Graves’ hyperthyroidism. They did not get
remissionsofGraves’hyperthyroidismandcontinuedtotake
ATD. Complex changes of TSAb were noted in 13 TSAb-
positive patients (IIb) (Figure 3(b)). One (IIb1) of the 13
patients with complex changes of TSAb got remissions, but
the other 12 patients (IIb2) did not get remissions. TSAb
disappeared in 73 (IIc) (74%) of the 98 TSAb-positive
Graves’ patients with hyperthyroidism (IIc) (Figure 3(c)).
With the disappearance of TSAb, 60 (IIc1) (82%) of the
73 patients, in whom TSAb had disappeared (IIc), got
remissions of Graves’ hyperthyroidism. Figures 3d1 and
3d2 show the changes of TSAb and TSBAb, respectively,
in the 2 patients with TSAb-positive Graves’ hyperthy-
roidism, who developed TSBAb-positive hypothyroidism
(IId) (Table 1, IId). In these 2 patients, TSAb was dom-
inant initially (Figure 3(d1)), and then TSBAb became
dominant (Figure 3(d2)). The 2 patients had TSAb-positive
Graves’ hyperthyroidism and then developed TSBAb-
positive hypothyroidism. They were treated with MMI, and
then treated with T4. Figure 4 demonstrates the clinical
course of one of these 2 patients with TSAb-positive Graves’
hyperthyroidism, who developed TSBAb-positive hypothy-
roidism (Table 1, IId). A 40-year-old woman with TSAb-
positive Graves’ hyperthyroidism developed TSBAb-positiveJournal of Thyroid Research 9
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Figure 4: Clinical course of one of the 2 patients, who had TSAb-positive Graves’ hyperthyroidism and then developed TSBAb-
positive hypothyroidism (Table 1, IId). A 40-year-old woman with TSAb-positive Graves’ hyperthyroidism developed TSBAb-positive
hypothyroidism.ShehadTSAb-positiveGraves’hyperthyroidism((a),)withundetectableserumTSH((b), •)andthendevelopedTSBAb-
positive hypothyroidism ((b),  ) with high serum TSH ((b), •). TSAb was dominant initially ((a), ), and then TSBAb became dominant
((b),  ). TBII ((b), ◦) reﬂects TSBAb- and TSAb-activity. A patient with TSAb-positive Graves’ hyperthyroidism developed TSBAb-positive
hypothyroidism. She was treated with MMI and then with T4.
hypothyroidism. TSAb was dominant initially (Figure 4(a)),
and then TSBAb became dominant (Figure 4(b)). She had
TSAb-positive Graves’ hyperthyroidism with undetectable
serum TSH and then developed TSBAb-positive hypothy-
roidism with high TSH. She was treated with MMI and then
treated with T4. She had a goiter over 10 years.
4. Discussion
We have reevaluated TSBAb and TSAb in 34 TSBAb-
positive patients with hypothyroidism and in 98 TSAb-
positive Graves’ patients with hyperthyroidism. Half of the
34 TSBAb-positive patients continued to have persistently
positive TSBAb, continued to have hypothyroidism and did
not recover from hypothyroidism. Ten of the 98 Graves’
patients continued to have positive TSAb. They continued
to have hyperthyroidism, and did not get remissions of
Graves’ hyperthyroidism. TSBAb had disappeared in 15 of
the 34 TSBAb-positive patients with hypothyroidism. With
the disappearance of TSBAb, recovery from hypothyroidism
was noted in 13 (87%) of the 15 TSBAb-positive patients.
TSAb had disappeared in 73 of the 98 TSAb-positive Graves’
patients with hyperthyroidism. With the disappearance of
TSAb, 60 (82%) of the 73 TSAb-positive patients got
remissions. Two of the 34 TSBAb-positive patients with
hypothyroidism developed TSAb-positive Graves’ hyper-
thyroidism. Two of the 98 TSAb-positive Graves’ patients
with hyperthyroidism developed TSBAb-positive hypothy-
roidism.TSBAbcauseshypothyroidism.TSAbcausesGraves’
hyperthyroidism. TSBAb and TSAb are TRAb. TSBAb-
positivehypothyroidismandTSAb-positivehyperthyroidism
may be two aspects of one disease (TRAb disease).
TSBAb blocks TSH-stimulation of the thyroidand causes
hypothyroidism. TSAb stimulates the thyroid and causes
Graves’hyperthyroidism.BothTSBAbandTSAbblockTSH-
binding to thyroid cells as TSH receptor antibodies (TRAbs),
which have been measured as TSH-binding inhibitory
immunoglobulin (TBII) [1–3, 13]. TBII reﬂects TSBAb- and
TSAb-activities. TBII measures the binding of antibody to
TSH receptor by competition with radiolabeled TSH and
does not distinguish between TSBAb and TSAb. TSBAb is
measured as a TSH-stimulation blocking assay and TSAb as
a stimulator assay. TSBAb is a blocking antibody [3, 13]a n d
TSAb is a stimulating antibody [1, 2, 13].
TSBAb-activities were expressed as percentage inhibition
of TSH-stimulated cAMP production by test IgG [3, 10–
13, 15–20]. Two formulas (TSBAb-A and TSBAb-B) have
been proposed to calculate TSBAb [3, 10–13]. TSBAb-A was
used in the earlier reports [3, 10–13], and TSBAb-B in the
later report [13]. TSBAb-A ignores TSAb activity in serum
andmightgivelowTSBAbactivity.TSBAb-BconsidersTSAb
activity in serum and might give high TSBAb activity. All
of the TSBAb-positive patients with hypothyroidism had
strongly positive TSBAb-A and TSBAb-B. Both TSBAb-A
and TSBAb-B could be used to estimate TSBAb activities
[13]. The details were discussed in the previous paper [13].
TSBAb, described in this paper, corresponds to TSBAb-A in
the previous paper [13]. TSBAb-A [13]i su s e da sT S B A bi n
this report.10 Journal of Thyroid Research
All of the 34 TSBAb-positive patients with hypothy-
roidism and all of the 98 TSAb-positive Graves’ patients had
positive TBII (TRAb). TSBAb and TSAb are TSH-receptor
antibodies (TRAbs), which have been measured as TBII.
TBII does not distinguish between TSBAb and TSAb. TBII
reﬂects TSBAb- and TSAb-activities [1–3, 13]. All of the 34
TSBAb-positive patients with hypothyroidism had strongly
positive TSBAb. Some of them had positive TSAb [13].
All of the 98 Graves’ patients had positive TSAb. Some
of them had positive TSBAb [13]. TSBAb-positve patients
with hypothyroidism had narrow distributions of TSBAb
and TSAb, and Graves’ patients with hyperthyroidism had
wide distributions of TSBAb and TSAb [13]. TSBAb-positive
patients with hypothyroidism have strongly positive TSBAb.
TBII reﬂects TSBAb- and TSAb-activities [1–3, 13].
Some of the TBII-positive patients have hypothyroidism,
and the other TBII-positive patients have hyperthyroidism.
The former TBII is TSBAb, and the latter TBII is TSAb.
The numbers of the former TSBAb-positive patients with
hypothyroidism are less than those of the latter TSAb-
positive Graves’ patients with hyperthyroidism. All of the
TSBAb-positive patients with hypothyroidism have high
titersofTBII,whichisTSBAb[3].Almostalloftheuntreated
Graves’ patients with hyperthyroidism have TBII, which is
TSAb [1, 2]. TSBAb- (TRAb-) positive hypothyroidism and
TSAb- (TRAb-) positive Graves’ hyperthyroidism may be
two aspects of one disease (TRAb disease).
Hypothyroidism may result from the production of
TSBAb [3]. In 1992, we followed 21 TSBAb-positive patients
with hypothyroidism over 10 years and found that with
the disappearance of TSBAb, recovery from hypothyroidism
was noted in 6 (40%) of the 15 TSBAb-positive patients
[3]. Here, we followed 34 TSBAb-positive patients with
hypothyroidism over 10 years and found that with the
disappearance of TSBAb, recovery from hypothyroidism was
noted in 13 (87%) of the 15 patients. The frequency of
recovery from hypothyroidism with the disappearance of
TSBAb in this paper is much higher than that in the previous
one [3]. With the disappearance of TSBAb, recovery from
hypothyroidism is observed. The production of TSBAb may
subside, producing remissions of hypothyroidism.
It is important to know whether a patient with Graves’
disease gets remission or not during ATD treatment. Dis-
appearance of TSAb predicted the remissions of Graves’
hyperthyroidism [14]. With the disappearance of TSAb, 36
(82%) of the 44 patients were reported to get remissions in
the previous paper [14] and 60 (82%) of the 73 patients are
reported to get remissions in this paper. Disappearance of
TSAb predicts the remissions of Graves’ hyperthyroidism.
Two of the 34 TSBAb-positive patients with hypothy-
roidism developed TSAb-positive Graves’ hyperthyroidism
(Ic). Two of the 98 TSAb-positive Graves’ patients with
hyperthyroidism developed TSBAb-positive hypothyroidism
(IId). In the former, TSBAb was dominant initially and then
TSAb became dominant. In the latter, TSAb was dominant
initially and then TSBAb became dominant. Thyroid func-
tion can oscillate between hypothyroidism and hyperthy-
roidism as TSBAb or TSAb becomes dominant. TSAb and
TSBAb can be used to document the functions of TRAb
[13]. TBII-positive patients with strongly positive TSBAb
have hypothyroidism. TBII-positive patients with posi-
tive TSAb have hyperthyroidism. TSBAb-positive patients
with hypothyroidism and TSAb-positive Graves’ patients
with hyperthyroidism may have both TSBAb and TSAb
[1, 2, 13, 21–26]. TSBAb-positive patients with hypothy-
roidism may develop TSAb-positive hyperthyroidism. TSAb-
positive Graves’ patients with hyperthyroidism may develop
TSBAb-positive hypothyroidism. TSBAb and TSAb are
TRAb. TSBAb- (TRAb-) positive hypothyroidism and TSAb-
(TRAb-)positive hyperthyroidismmaybetwoaspectsofone
disease (TRAb disease).
In Japan, TRAb has been measured as TBII and TSAb
[14]. TSAb is a bioassay, using porcine thyroid cells. We
usually measure TSAb, using a commercially available kit
[14]. In Japan, TSAb-assay kit is available, but TSBAb-
assay kit is not. When a patient has hypothyroidism with
elevated TSH and positive TBII, this TBII is thought to be
TSBAb. We usually do not measure TSBAb. Practically, when
a patient with hypothyroidism has positive TBII, this TBII
may be TSBAb. When a patient with hyperthyroidism has
positive TBII, this TBII may be TSAb. TSAb and TSBAb can
be used to document TRAb-function. TBII, measuring the
antibody-binding to the receptor by competition with radio-
labeledTSH,doesnotdistinguishbetweenTSAbandTSBAb.
A positive TBII result in a patient with hypothyroidism
is evidence for the presence of TSBAb. A positive TBII
result in a patient with hyperthyroidism is evidence for
the presence of TSAb. These bioassays (TSAb and TSBAb)
are useful to detect transient neonatal hyperthyroidism and
hypothyroidism [10] and are also important to conﬁrm the
causes of hyperthyroidism and hypothyroidism [13]. TBII-
positivepatientsmayhaveTSBAborTSAb.Thyroidfunction
can oscillate between hypothyroidism and hyperthyroidism
as TSBAb or TSAb becomes dominant. TSAb and TSBAb can
be used to document TRAb-function [13].
There are two forms of autoimmune thyroiditis: atrophic
autoimmune thyroiditis and goitrous autoimmune thy-
roiditis [3]. We followed 34 TSBAb-positive patients with
hypothyroidism (24 patients with atrophic autoimmune
thyroiditis and 10 with goitrous autoimmune thyroiditis)
over 10 years. TSBAb has been found in patients with
atrophic autoimmune thyroiditis, and also in patients with
goitrous autoimmune thyroiditis [11]. All of the 10 TSBAb-
positive patients with goitrous autoimmune thyroiditis
recovered from hypothyroidism and 19 (79%) of the 24 with
atrophicautoimmunethyroiditiscontinuedtohavehypothy-
roidism. With the disappearance of TSBAb, recovery from
hypothyroidism has been seen. TSBAb-positive hypothyroid
patients with goitrous autoimmune thyroiditis may recover
from hypothyroidism, and those with atrophic autoimmune
thyroiditis may continue to have hypothyroidism.
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